Caucasus Medical Centre

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Endometrial cancer2 trials
• Lung cancer2 trials
• Lupus (SLE)2 trials
• Pancreatic cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 37 trials
• Phase 21 trial
• Phase 2/31 trial

Status

• Recruiting6 trials
• Active, not recruiting3 trials

Lead sponsor

• Regeneron Pharmaceuticals2 trials
• BioNTech SE1 trial
• Immuneering Corporation1 trial
• Janssen Research & Development, LLC1 trial
• Kartos Therapeutics, Inc.1 trial
• and 3 more

Running trials

• Recruiting

  BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

  NCT07625644· Phase 3· SystImmune Inc.· Source

  Contact: Ivane Kiladze (principal investigator)

• Recruiting

  Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07562152· Phase 3· Immuneering Corporation· Source

  Contact: Nino Khunashvili

• Recruiting

  REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

  NCT07410117· Phase 3· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Recruiting

  A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  NCT07438496· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

  NCT07173751· Phase 3· BioNTech SE· Source

• Recruiting

  Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

  NCT05797831· Phase 2/3· Kartos Therapeutics, Inc.· Source

  Contact: John Mei

• Active, not recruiting

  A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus

  NCT05672576· Phase 3· Viatris Innovation GmbH· Source

• Active, not recruiting

  A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

  NCT05557591· Phase 2· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

  NCT05611931· Phase 3· Karyopharm Therapeutics Inc· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Endometrial cancer1 recruiting
• Lung cancer1 recruiting
• Lupus (SLE)1 recruiting
• Pancreatic cancer1 recruiting
• Triple-negative breast cancer1 recruiting